As per the report published by Fior Markets ,the global aminoglycosides market is expected to grow from USD 1.56 Billion in 2018 to USD 2.78 Billion by 2026 at a CAGR of 7.5% during the forecast period 2019-2026. Asia Pacific is dominating the market due to the rising incidence rate of multi-drug resistant tuberculosis that needs second-line drugs for treatment in the region along with the substantial availability of other aminoglycosides as well. The presence of a number of market entities in economies such as Japan, China, and India are attributive towards the high potential for market share in this region.
Aminoglycosides Market by Product (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Other Aminoglycosides), Route of Administration, Application Region Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2019 to 2026.
DOWNLOAD FREE SAMPLE REPORT AT:https://www.fiormarkets.com/report-detail/396101/request-sample
Leading companies in the industry include Kremoint Pharma Pvt. Ltd, Vega Pharma Ltd., Jiangxi Bolai Pharmacy Co., Ltd., Xian Wison Biological Technology Co., Ltd., Hangzhou Uniwise International Co., Ltd., HuvePharma, Yi Chang Veterinary Medicine Factory, Medson Pharmaceuticals, Medico Remedies Pvt. Ltd, andamong others. In order to enhance market position, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership.For instance, in July 2018, Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced that ZEMDRI would be available for ordering.
Aminoglycoside is a classification of conventional gram-negative antibacterial agents that restrain protein synthesis. It is used for the treatment of various bacterial infections in humans and animals.The aminoglycosides market is segmented on the basis of product, application and route of administration.The product segment is classified as neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, kanamycin and other aminoglycosides. Neomycin segment is dominating the market with the highest share of 26.50% in 2018. Neomycin and tobramycin together contribute revenue in this market due to an increasing usage and prescription of these drugs for the treatment of different bacterial infections. Neomycin finds higher usage in topical formulations for the treatment of different skin infections. The route of administration segment is divided into segments such as feed, injectables (parenteral), intra-mammary, topical and oral.Neomycin finds higher usage in topical formulations for the treatment of different skin infections. Neomycin helps in stopping the growth of bacteria in the intestines and is also used along with a special diet to treat a certain serious brain problem. The injectables segment is dominating the market and valued around USD 613.43 Million. The injectables are preferred for human medical usage more because they provide the optimum mode of drug action mechanism through intravenous or intramuscular route for treatment. The application segment includes veterinary, skin infection, respiratory diseases, UTI & pelvic diseases, and other diseases. The respiratory diseases segment is dominating with the highest share of 41.30% in 2018 owing to rising instances of tuberculosis in the developing regions across the globe. Furthermore, the increase in incidences of multi-drug resistant tuberculosis is attributive towards growth in the respiratory diseases segment.
Browse full report with TOC at:https://www.fiormarkets.com/report/aminoglycosides-market-by-product-neomycin-tobramycin-gentamicin-amikacin-396101.html
Dynamics driving the growth of the market include growing instances of animal disease outbreaks, increasing number of cases of tuberculosisand introduction of digital health agenda by WHO and ERS.On the other hand theregulatory disapproval for the usage of certain aminoglycosideis restricting the growth of aminoglycosidesmarket. However,existence of yearly procurement requirement by GDF and STOP TB Foundation is projected to spur the demand in forthcoming years.The reduced consumption and production of combinatorial pharmaceuticals involving usage of intramammary and injectable aminoglycosides is posing a challenge to the market.
Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (email@example.com), who will ensure that you get a report that suits your needs.